FDA Medical Device Advertising and Promotion Compliance Guide (2026)

FDA Is Intensifying Enforcement on Medical Device Promotion — Here Is What You Need to Know

In 2025, the FDA issued over 200 enforcement letters challenging advertising and promotion across drugs, biologics, and medical devices. While most enforcement activity has focused on pharmaceuticals, the regulatory framework for medical device promotion carries the same fundamental risk: the Federal Food, Drug, and Cosmetic Act (FFDCA) is a strict liability criminal statute. Promotional claims that are false, misleading, or fail to fairly balance benefits with risks can lead to enforcement letters, reputational damage, and criminal misbranding charges.

For medical devices specifically, the FDA's Center for Devices and Radiological Health (CDRH) — through its Office of Product Evaluation and Quality (OPEQ) — issues warning letters for promotional violations. In 2025, OPEQ issued 32 enforcement letters targeting medical device marketing violations, including warning letters to manufacturers making claims outside their cleared intended use, devices incorporating AI-based algorithms promoted without proper authorization, and failures to apply Unique Device Identifiers and submit GUDID data.

This guide covers the complete regulatory framework for medical device advertising and promotion: FDA labeling requirements, the distinction between labeling and advertising, enforcement mechanisms, off-label communication rules, social media compliance, FTC overlap, and practical strategies for maintaining compliant promotional materials.

Regulatory Framework: Who Regulates Device Promotion

FDA Authority

The FDA regulates medical device promotion through multiple legal authorities:

FTC Authority

The Federal Trade Commission (FTC) has overlapping authority over medical device advertising through:

• Section 5 of the FTC Act: Prohibits unfair or deceptive acts or practices
• Truth-in-advertising standards: Claims must be truthful, not misleading, and substantiated
• FTC Act Section 12: Specific provisions for false advertisements for food, drugs, devices, and cosmetics

In practice, the FDA focuses on labeling and promotional materials that accompany or supplement the device, while the FTC focuses on advertising claims in broader media. However, both agencies can act against the same promotional content.

The Distinction Between Labeling and Advertising

This distinction is critical for medical devices:

The FDA defines "labeling" extremely broadly — any material that accompanies the device or is used to promote it can be considered labeling. This includes website content, trade show materials, sales training documents, and even social media posts.

21 CFR Part 801: Core Labeling Requirements

General Labeling Requirements (21 CFR 801.1 — 801.60)

All medical devices distributed in the United States must bear labels that include:

Prescription Device Labeling (21 CFR 801.109)

Prescription devices are exempt from the requirement for "adequate directions for use" on the label itself, provided that:

• The device is in the possession of a person regularly licensed to prescribe or administer it
• The labeling includes the symbol statement "Rx only" or "Caution: Federal law restricts this device to sale by or on the order of a physician"
• Adequate directions for use are provided to the practitioner in the form of professional labeling

Promotional Labeling vs Product Labeling

Promotional labeling is any labeling material beyond the device's immediate package that is used to promote the device. This includes:

• Brochures and catalogs
• Website content describing device features and benefits
• Sales training materials
• Conference presentations and exhibit materials
• Videos and animations
• Mobile applications promoting the device
• Press releases making product claims

All promotional labeling must be consistent with the device's cleared or approved intended use. Claims that go beyond the authorized indication constitute a new intended use and may trigger a requirement for additional premarket review.

Enforcement Mechanisms and Recent Trends

FDA Enforcement Tools

The FDA has several enforcement mechanisms for device promotion violations:

2025 Enforcement Trends

The most significant enforcement trend in 2025 was the dramatic escalation in FDA promotional enforcement:

• September 9, 2025: HHS and FDA announced a broad crackdown on deceptive advertising, issuing over 100 enforcement letters in a single day
• Over 200 total enforcement letters were issued in 2025 for advertising and promotion violations
• 74 letters were issued to pharmaceutical and biologic manufacturers (10 Warning Letters, 64 Untitled Letters)
• Device-specific actions included warning letters for breast binder manufacturers whose promotional claims reflected intended uses outside their exempt classification (product code HEF)
• AI algorithm claims: At least two warning letters cited devices incorporating AI-based algorithms promoted without proper authorization
• UDI enforcement: Five warning letters cited failures to apply UDI and submit GUDID data
• RUO enforcement: One warning letter cited marketing of a Research Use Only (RUO) IVD for clinical diagnostic use

Device Enforcement Examples

Off-Label Promotion and Communication

The General Prohibition

Promoting a device for uses outside its cleared or approved indications (off-label promotion) is generally prohibited. Such promotion can:

• Render the device misbranded under the FD&C Act
• Create a new intended use requiring separate premarket authorization
• Trigger enforcement action by the FDA

Permitted Off-Label Communications

There are limited circumstances where off-label information can be communicated:

Responding to Unsolicited Requests

When responding to unsolicited requests for off-label information, firms must:

• Provide truthful, balanced, and non-misleading responses
• Include a copy of the approved/cleared labeling
• Disclose that the use is not approved/cleared
• Provide information about risks and limitations
• Not proactively promote the response beyond the individual request

Social Media and Digital Advertising Compliance

FDA Guidance on Digital Platforms

The FDA has issued specific guidance documents addressing digital promotion:

Social Media Compliance Checklist

The WHOOP Warning Letter (2025)

The FDA's 2025 warning letter to WHOOP illustrates how marketing and feature framing can trigger device classification. WHOOP was found to have promoted its wearable device with claims implying clinical utility beyond general wellness, crossing the line from wellness tracking to medical device territory. The case underscores that intended use — as reflected in marketing claims — determines regulatory status.

FTC Requirements for Medical Device Advertising

Truth-in-Advertising Standards

The FTC requires that all advertising claims for medical devices be:

Substantiation Requirements

The level of substantiation required depends on the type of claim:

Comparison: FDA vs FTC Regulation of Device Promotion

Practical Compliance Framework

Building a Promotional Review Process

An effective Medical, Legal, and Regulatory (MLR) review process should include:

Claims Substantiation Best Practices

1. Create a claims library: Maintain a centralized database of all approved claims with supporting evidence citations
2. Map claims to clearance/approval: Every promotional claim must trace back to the cleared or approved intended use
3. Document substantiation: For each claim, document the supporting data source (510(k) summary, PMA clinical data, bench testing reports)
4. Review all channels: Ensure compliance across all promotional channels — website, social media, trade shows, sales aids, press releases
5. Train the field force: Sales representatives must understand the boundary between on-label and off-label communication

Managing Third-Party Content

Companies are responsible for promotional content they create, influence, or approve — even when distributed through third parties:

FAQ

What is the difference between medical device labeling and advertising?

Labeling includes any written, printed, or graphic material that accompanies or supplements the device — brochures, IFUs, websites, videos, and mobile apps. Advertising includes promotional communications in broader media — digital ads, trade show materials, social media. The FDA regulates both under misbranding provisions; the FTC also has authority over advertising.

Can I promote my device for uses not included in the 510(k) clearance?

Generally no. Promoting a device for uses outside its cleared or approved indications constitutes off-label promotion and can render the device misbranded. Limited exceptions exist for responding to unsolicited requests, distributing peer-reviewed scientific publications, and communications consistent with FDA-required labeling. Each of these has specific conditions that must be met.

What happens if the FDA finds my promotional materials are misleading?

The FDA may issue a Warning Letter (for serious violations) or an Untitled Letter (for less serious violations). Both are publicly posted. The company is expected to take prompt corrective action. Failure to address violations can result in seizure, injunction, or criminal prosecution for misbranding. The FFDCA is a strict liability criminal statute.

Do social media posts about my device need to comply with FDA regulations?

Yes. Social media posts are considered labeling or promotional material if they make claims about a device. The FDA's guidance on Internet/Social Media Platforms requires that even character-limited posts include the most significant risks and link to complete risk information. Company-created content and content the company influences are both subject to regulation.

What is "fair balance" in device promotion?

Fair balance requires that promotional materials present benefit and risk information in a balanced manner. Benefit claims should not be presented without corresponding risk information. The presentation should not be misleading through disproportionate emphasis on benefits. This applies to all promotional materials including websites, brochures, videos, and social media.

Who enforces medical device advertising — FDA or FTC?

Both agencies have authority. The FDA focuses on labeling and promotional materials that accompany or supplement the device, regulating them under misbranding provisions of the FD&C Act. The FTC focuses on advertising claims in broader media, requiring they be truthful, not misleading, and substantiated. In practice, both agencies can act against the same promotional content, and companies must comply with both sets of requirements.

What substantiation is required for device performance claims in advertising?

Performance claims must be supported by competent and reliable scientific evidence. The level of evidence depends on the claim: efficacy claims generally require clinical or bench testing data; comparative claims require head-to-head testing; safety claims require comprehensive safety data. The substantiation must exist at the time the claim is made, not after the fact.

What are the Form FDA 2253 submission requirements?

Form FDA 2253 requires manufacturers to submit specimens of promotional labeling and advertising to the FDA at the time of initial dissemination. For prescription devices, this includes all promotional materials. For interactive promotional media, real-time communications may be submitted quarterly. The FDA processes tens of thousands of Form 2253 submissions annually.

Can I use patient testimonials in device promotion?

Patient testimonials are considered promotional labeling and must comply with all applicable requirements. Testimonials must be truthful, not misleading, and consistent with the cleared or approved intended use. They must not overstate the benefits or omit material risk information. The company is responsible for the content of testimonials it uses in promotion.